Show simple item record

dc.contributor.authorFEBRIANTI, Riska Ayu
dc.contributor.authorNARULITA, Erlia
dc.date.accessioned2022-09-01T03:47:26Z
dc.date.available2022-09-01T03:47:26Z
dc.date.issued2022-02-26
dc.identifier.govdocKodeprodi#0210183#pendidikanbiologi
dc.identifier.urihttps://repository.unej.ac.id/xmlui/handle/123456789/109187
dc.description.abstractObjectives: This study aimed to produce a recombinant protein vaccine candidate based on an epitope of spike protein from Indonesian SARS-CoV-2 to provide immunogenicity and protection against future infection. Methods: A reverse vaccinology approach was used to identify potential vaccine candidates by screening the pathogen’s genome through computational analyses. Results: Epitope vaccine candidates with the amino acid sequence of FKNHTSPDV were selected. This peptide is hydrophilic, does not induce autoimmune and allergic reactions, is antigenic, is classified as a stable protein, and is predicted to be present in the cell membrane. The selected epitope sequences were inserted into the plasmid vector pcDNA3.1(þ) N-GST (thrombin). Inclusion of additional features of the gene encoding glutathione-S transferase, which can increase antigen expression and solubility, and the genes encoding NSP 1e4 proteins, which are essential in replication, added value to the produced recombinant protein. Conclusion: Recombinant protein vaccine candidates with the FKNHTSPDV epitope have parameters sufficient for production on a laboratory scale for further testing.en_US
dc.language.isoenen_US
dc.publisherJournal of Taibah University Medical Sciencesen_US
dc.subjectINDONESIAen_US
dc.subjectRecombinant proteinen_US
dc.subjectReverse vaccinologyen_US
dc.subjectSARS-CoV-2en_US
dc.subjectSpike proteinen_US
dc.titleIn-Silico Analysis of Recombinant Protein Vaccines from Spike Protein Indonesian SARS-CoV-2 Using A Reverse Vaccinology Approachen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record